After a another grim day in new COVID-19 cases, hospitalizations and deaths, a glimmer of hope on the vaccine front was provided when Pfizer Inc. said it has enough data on its vaccine candidate’s safety to seek emergency-use authorization from the Food and Drug Administration.
After a another grim day in new COVID-19 cases, hospitalizations and deaths, a glimmer of hope on the vaccine front was provided when Pfizer Inc. said it has enough data on its vaccine candidate’s safety to seek emergency-use authorization from the Food and Drug Administration.